Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GMAB)
NASDAQ:GMAB
GMAB Analyst Ratings
Moderate Buy
4 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
GMAB Stock 12 Month Forecast
Average Price Target
$32.75
▲(31.68% Upside)
| Highest Price Target$46.00 | Average Price Target$32.75 | Lowest Price Target$24.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TR | OpenAI - 4o
$26→$28
Buy
12.59%
Upside
Reiterated
08/20/25
H.C. Wainwright
$35→$36
Buy
44.75%
Upside
Reiterated
08/15/25
Genmab's Strong Financial Performance and Promising Pipeline Drive Buy RatingValuation and Risks. We use a DCF-based approach to valuing 2.0% terminal growth rate, 8.0% discount rate, and 23% effective tax rate. We assign a 90% probability of approval to DARZALEX in smoldering 40% probabilities of approval to tisotumab vedotin for 1L and 2L cervical cancer and 2L+ ovarian cancer, respectively; a 60% and 100% probability to epcoritamab in front-line and r/r DLBCL, respectively, and a 100% probability of approval in r/ r FL; a 65-100% probability to teclistamab in MM; and 15% probabilities to both in solid tumors.
Leerink Partners
―
Buy
―
Reiterated
08/14/25
Genmab's Strategic Growth and Clinical Advancements: A Compelling Investment OpportunityWe hosted GMAB management for a group lunch in New York City today where we discussed several topics, with a focus on long-term revenue growth as well as the development path for Rina-S and epcoritamab. Recall, GMAB is a high-quality commercial-stage cash flow positive company. The story has historically been driven by royalties they receive from JNJ (MP, Risinger) on Darzalex (daratumumab, anti-CD38, partnered with JNJ), which represents >60% of their current revenues. Investors were eager to hear from management about the company's strategy of driving long-term growth in a post-Darzalex royalties era.
Truist Financial
$46
Buy
84.96%
Upside
Reiterated
08/08/25
TD Cowen
$20→$24
Hold
-3.50%
Downside
Reiterated
08/07/25
William Blair
―
Buy
―
Reiterated
08/07/25
Morgan Stanley
$25
Hold
0.52%
Upside
Reiterated
07/02/25
Goldman Sachs
$35.5→$29
Hold
16.61%
Upside
Reiterated
01/27/25
Bernstein
―
Hold
―
Upgraded
12/20/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TR | OpenAI - 4o
$26→$28
Buy
12.59%
Upside
Reiterated
08/20/25
H.C. Wainwright
$35→$36
Buy
44.75%
Upside
Reiterated
08/15/25
Genmab's Strong Financial Performance and Promising Pipeline Drive Buy RatingValuation and Risks. We use a DCF-based approach to valuing 2.0% terminal growth rate, 8.0% discount rate, and 23% effective tax rate. We assign a 90% probability of approval to DARZALEX in smoldering 40% probabilities of approval to tisotumab vedotin for 1L and 2L cervical cancer and 2L+ ovarian cancer, respectively; a 60% and 100% probability to epcoritamab in front-line and r/r DLBCL, respectively, and a 100% probability of approval in r/ r FL; a 65-100% probability to teclistamab in MM; and 15% probabilities to both in solid tumors.
Leerink Partners
―
Buy
―
Reiterated
08/14/25
Genmab's Strategic Growth and Clinical Advancements: A Compelling Investment OpportunityWe hosted GMAB management for a group lunch in New York City today where we discussed several topics, with a focus on long-term revenue growth as well as the development path for Rina-S and epcoritamab. Recall, GMAB is a high-quality commercial-stage cash flow positive company. The story has historically been driven by royalties they receive from JNJ (MP, Risinger) on Darzalex (daratumumab, anti-CD38, partnered with JNJ), which represents >60% of their current revenues. Investors were eager to hear from management about the company's strategy of driving long-term growth in a post-Darzalex royalties era.
Truist Financial
$46
Buy
84.96%
Upside
Reiterated
08/08/25
TD Cowen
$20→$24
Hold
-3.50%
Downside
Reiterated
08/07/25
William Blair
―
Buy
―
Reiterated
08/07/25
Morgan Stanley
$25
Hold
0.52%
Upside
Reiterated
07/02/25
Goldman Sachs
$35.5→$29
Hold
16.61%
Upside
Reiterated
01/27/25
Bernstein
―
Hold
―
Upgraded
12/20/24
Best Analysts Covering Genmab
1 Month
xxx
Success Rate
8/15 ratings generated profit
Average Return
-1.29%
reiterated a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 53.33% of your transactions generating a profit, with an average return of -1.29% per trade.
3 Months
xxx
Success Rate
8/21 ratings generated profit
Average Return
-0.77%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 38.10% of your transactions generating a profit, with an average return of -0.77% per trade.
1 Year
Success Rate
9/21 ratings generated profit
Average Return
-4.90%
reiterated a buy rating 25 days ago
Copying Asthika Goonewardene's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of -4.90% per trade.
2 Years
xxx
Success Rate
9/21 ratings generated profit
Average Return
-6.75%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 42.86% of your transactions generating a profit, with an average return of -6.75% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
GMAB Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
4
5
4
3
3
Buy
12
18
16
15
15
Hold
23
18
10
5
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
39
41
30
23
21
Each month's total comprises the sum of three months' worth of ratings.
GMAB Financial Forecast
GMAB Stock Forecast FAQ
What is GMAB’s average 12-month price target, according to analysts?
Based on analyst ratings, Genmab A/S’s 12-month average price target is 32.75.
What is GMAB’s upside potential, based on the analysts’ average price target?
Genmab A/S has 31.68% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is GMAB a Buy, Sell or Hold?
Genmab A/S has a consensus rating of Moderate Buy which is based on 4 buy ratings, 2 hold ratings and 0 sell ratings.
What is Genmab A/S’s price target?
The average price target for Genmab A/S is 32.75. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $46.00 ,the lowest forecast is $24.00. The average price target represents 31.68% Increase from the current price of $24.87.
The highest analyst price target is $46.00 ,the lowest forecast is $24.00. The average price target represents 31.68% Increase from the current price of $24.87.
What do analysts say about Genmab A/S?
Genmab A/S’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of GMAB?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.